Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader

Fig. 2

a Co-registered FES-PET/CT imaging of MCF7-Y537S xenograft tumor-bearing mice at 8 h (bid regimen) or 24 h (qd regimen) after 4 days of administration of SAR439859. b Individual data and mean ± SD of ΔSUVmean for [18F]-FES uptake during different regimen of SAR439859 treatment. c ERα staining and d ER-positive cells quantification in vehicle and SAR439859-treated tumor samples

Back to article page